Advanced Diagnostics · Genomic Medicine
Your Genome Has the Answers. Now Medicine Can Read Them.
One sample. A complete picture of your hereditary risks, disease susceptibility, and medication compatibility — with results that evolve as the science does.
Why Whole-Genome
Most genetic risk is invisible to standard medicine. Not anymore.
Standard panels — cholesterol, PSA, family history — miss the genetic layer entirely. They assess surface markers. They don't read your DNA.
Whole-genome sequencing integrates your complete genetic blueprint with your clinical profile, producing personalized risk insights that evolve with the science over your lifetime.
Of coronary artery disease risk is hereditary — invisible to standard lipid panels
Of prostate cancer risk is hereditary — invisible to PSA testing alone
Of people carry no single high-risk gene — yet may carry significant polygenic risk
Medications analyzed for your individual genetic response
Three Tests
One genome. Three clinical windows into your risk.
Order individually or together from a single sample. CLIA-certified, CAP-accredited laboratory. Results in 5–6 weeks.
Single-Gene Risk
Screens 84–151 actionable genes for pathogenic variants linked to adult-onset cancers, cardiovascular disease, and metabolic disorders — even without a family history.
- Cancers — BRCA1/2, Lynch syndrome, familial colon, prostate, ovarian, skin
- Cardiovascular — Cardiomyopathies, arrhythmias, familial hypercholesterolemia
- Other — Clotting disorders, metabolic disease, metal metabolism
- Continuous re-analysis — results update as databases advance
Medication Response
Analyzes how your genes affect medication processing. Done once — relevant to every prescription you'll ever receive. Especially valuable for hormone therapy, GLP-1s, statins, and psychiatric medications.
- Identifies poor metabolizers, ultra-rapid metabolizers, and dose-sensitivity profiles
- Informs Mend protocols — TRT dosing, GLP-1 response, statin selection, antidepressants, pain management
- Reduces trial-and-error prescribing from day one
- Permanent reference — share with any future provider
iPRS — Integrated Polygenic Risk Score
Personalized absolute risk estimates for prostate cancer, breast cancer, and coronary artery disease — combining whole-genome sequencing with your clinical factors.
What is a polygenic risk score? Most people carry no single high-risk gene — but may still carry significant cumulative risk from hundreds of thousands of small variants. iPRS aggregates those variants and integrates them with clinical factors like age, PSA, and BMI to produce an absolute percentage risk your practitioner can act on.
Prostate Cancer Risk
Absolute 10-year and lifetime risk. Validated in 140,000+ individuals. 8.6% of men without family history showed ~3× elevated incidence.
Breast Cancer Risk
5-year and lifetime risk via Tyrer-Cuzick enhanced with genomic data. Up to 20% of hereditary risk is missed by BRCA1/2 alone. Up to 6% of women reclassified from low- to high-risk.
Heart Disease Risk
Absolute 10-year CAD risk — more accurate than ASCVD scoring alone. Nearly 10% of borderline-risk patients reclassified as high-risk.
The Process
Simple from Start to Insight
In-person at Mend in Flagstaff, or via at-home kit for Arizona telehealth patients.
Sample Collection
Blood draw or buccal swab. One sample covers all three tests — collected in-office or sent as an at-home kit.
Sequencing & Analysis
Clinical-grade 30× whole-genome sequencing at a CLIA-certified, CAP-accredited lab. Results in 5–6 weeks.
Practitioner Review & Counseling
Your Mend practitioner walks through every result — translating risk scores into clear, personalized next steps.
FAQ
Common Questions
Related Testing
Diagnostics Often Ordered Together
Your Genome Has Been Speaking.
Time to Listen.
Most people learn about their genetic risks after a diagnosis. A genomics consultation at Mend changes that timeline.